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with TNF-a is reported to result in pronounced insulin resistance [9] .
Thiazolidinediones are a new class of drugs that increase sensitivity to insulin [10] . They lower plasma insulin concentrations and enhance insulin action in obese diabetic animals [11] . In Type II diabetic patients, thiazolidinediones reduce basal and postprandial blood glucose values as well as HbA 1 c and fructosamine values [10] . Recently, thiazolidinediones have been shown to be the ligands for the peroxisome proliferator-activated receptor (PPAR)g, an orphan member of the nuclear receptor superfamily of ligand-activated transcription factors [12] , which has been recognized to be the functional receptor in anti-diabetic action of thiazolidinediones. However, the exact linkage between PPARg activation and an improvement of insulin resistance by thiazolidinediones has not been fully explained.
We hypothesize that the anti-diabetic mechanism of thiazolidinediones depends on the quantity of PPARg mRNA in the insulin resistant state especially in the state where inflammatory cytokines play a part. Our study was therefore designed to determine whether inflammatory cytokines change PPARg mRNA expression and, if so, whether thiazolidinediones restore the activity of inflammatory cytokines on PPARg mRNA expression. To answer these questions, we first isolated rat PPARg1 and PPARg2 cDNAs and examined the effect of various inflammatory cytokines and also some intracellular signalling factors on the regulation of PPARg mRNA expression in cultured rat mature adipocytes. We further investigated the effect of thiazolidinediones on the regulation of PPARg in the presence of TNF-a.
Materials and methods

Molecular cloning of rat PPARg1 and g2 complementary DNAs (cDNAs). Complementary DNAs for PPARg1 and g2
were prepared by the reverse transcription-polymerase chain reaction (RT-PCR). Using a DNA synthesizer (model 381A; Applied Biosistems, Foster City, Calif., USA), three oligonucleotide primers P-1 (5 ¢-ACAAGACTACCCTTTACTGAA-ATTACC-3 ¢), P-2 (5 ¢-TACAGCAAATCTCTGTTTTATG-CTGTT-3 ¢) and P-3 (5 ¢-ATTTCTTAGGTGTCAGATTTTT-TTCCCTCA-3 ¢) were synthesized which are based on the published mouse PPARg1 and g2 sequences [13] . Primer P-1 consisted of the 27 nucleotides upstream of the mouse PPARg1 ATG initiator Met. Primer P-2 also consisted of the nucleotides upstream of the mouse PPARg2 ATG initiator Met. Primer P-3 possessed the complement to the terminal 30 nucleotides downstream of the mouse sequence common to PPARg1 and g2. The primer pairs P-1/P-3 and P-2/P-3 were used in PCR reactions to generate full length rat cDNAs for PPARg1 and PPARg2, respectively. First-stranded cDNAs were synthesized from 10 mg of total RNA from Sprague-Dawley rats epididymal fat pads by the oligo (dT)-primed reverse transcription (Superscript, Gibco, Grand Island, N. Y., USA) and subjected to the PCR (KOD Dash; Toyobo, Osaka, Japan). The reaction profile was as follows: denaturation at 94°C for 30 s, annealing at 52°C for 2 s and extension at 74°C for 30 s for 30 cycles. The PCR products of predicted size were isolated and further subcloned into pGEM-T vector (Promega, Madison, Wis., USA) for sequencing.
DNA sequencing. Sequence determination of subcloned PCR products was carried out by the dideoxy chain termination method using Sequenase version 2.0 (U. S. Biochemical, Cleveland, Ohio, USA). Direct sequencing of the RT-PCR products was also done using PRISM sequenase fluorescent dye-labelled dideoxynucleotide kit (Applied Biosystems, Foster City, Calif., USA). All DNA sequences were confirmed by reading both DNA strands.
Isolation of rat mature adipocytes and cell incubation. Male Sprague-Dawley rats (200 g, Shimizu Experimental Supplies, Kyoto, Japan) were used throughout. The epididymal fat pads were removed, minced and digested with collagenase (type 2, Sigma Chemical, St. Louis, Mo., USA) for 60 min. at 37°C under continuous shaking (150 cycles per minute). The dispersed tissues were filtered through a nylon mesh with a pore size of 250 mm and centrifuged, thereby giving rise to floating mature adipocytes [14] . The mature adipocytes were incubated in DMEM with 5 % bovine serum albumin, 500 IU/ml penicillin and 500 mg/ml streptomycin at 37°C in 5 % CO 2 for the time indicated in the figures with or without the following agents: recombinant human TNF-a, human IL-1a (Dainihon Pharmaceutical, Osaka, Japan), rat IL-1b, rat IL-6, human LIF (Immugenex, Los Angeles, Calif., USA), porcine TGF-b (R & D Systems, Minneapolis, Minn., USA), 8-bromoadenosine-3 ¢:5 ¢-cyclic-monophosphate (8-Br-cAMP), 8-bromoguanosine-3 ¢:5 ¢-cyclic-monophosphate (8-Br-cGMP), phorbol 12-myristate 13-acetate (PMA), lysophosophatidylcholine (Lyso-PC) (Sigma Chemical), hydrogen peroxide (H 2 O 2 ) (Kanto Chemical, Tokyo, Japan), troglitazone (Sankyo, Tokyo. Japan), pioglitazone (Takeda Chemical Industries, Osaka, Japan). As the compounds used in the study were solubilized in DMSO, control cells were treated with matching concentrations of DMSO, and the final concentrations of DMSO were kept below 0.05 %. Our culture medium did not contain insulin or cortisol.
Northern blot analysis. Northern blot analysis was done as described [15] using 32 P-labelled cDNA probes. Rat PPARg1 cDNA fragments subcloned into pGEM-T vectors were digested with HincII and EcoRI and the resulting inserts (744 bp long) used as probes common to PPARg1 and g2 mRNA expression. The cDNA probe for glucose transporter 4 (GLUT4) [16] was obtained from G. I. Bell (University of Chicago, Ill., USA). A human b-actin genomic probe (Wako Pure Chemical, Osaka, Japan) was used to monitor the amount of total RNA in each sample. The cDNA probe for lipoprotein lipase (LPL) and ob, the gene for leptin, were obtained using the polymerase chain reaction as described previously [17] . Messenger RNA expression for PPARg and GLUT4 were normalized to b-actin mRNA expression and given as percent of the values detected in the control cultured rat adipocytes for the respective genes.
Reverse transcription and amplification of cDNAs. Of the total RNA 0.1 mg was reverse-transcribed. The transcribed cDNA was then used for PCR amplification to estimate the expression of rat PPARg1, PPARg2, rat TNF-a receptor (mouse TNF-a receptor type I homologue) [18] and b-actin. The PPARg1 primer pair P-1 and P-4 (5 ¢-GTCTTCATAGTGTG-GAGC AGAAATGCTG-3 ¢) generates a fragment of 177 bp, which is based on our rat PPARg1 sequence. The PPARg2 primer pair P-2 and P-4 generates a fragment of 267 bp, which is based on the rat PPARg2 sequence we cloned. The b-actin primer pair (5 ¢-TGGAGAAGAGCTATGAGCTGCCTG-3 ¢), (5 ¢-GTGCCACCAGACAGCACTGTGTTG-3 ¢) generates a fragment of 201 bp. The rat TNF-a receptor primer pair (5 ¢-GGTGACCGGGAGAAGAGGGATAAT-3 ¢), (5 ¢-GA ATCCGCGTGGCAGTTACACAC-3 ¢) generates a fragment of 411 bp.
Glucose uptake in rat mature adipocytes. Uptake of 2-deoxyglucose by mature adipocytes was measured as described previously [19] . Briefly, cells were incubated with the test agents for 24 h in DMEM with 5 % bovine serum albumin before the assay. The 100 ml of adipocyte cell suspension was pipetted into minisorp tube (Nunc, Roskilde, Denmark) and incubated in the presence or absence of insulin (10 ±7 mol/l). After 30 min of incubation, 50 ml of 2-deoxy-D-3 H-glucose (0.625 mCi/ml:2.315´10 4 Bg/ml) was added and the incubation continued for another 6 min at 37°C. Glucose uptake was stopped by addition of cytochalasin B (Sigma Chemical). Samples of cells were separated from the incubation medium by centrifugation through dinonyl phthalate oil, and then the amounts of radioactivity of separated cells were determined by liquid scintillation counting. The non-specific rate of 2-deoxyglucose uptake was obtained by adding cytochalasin B prior to the addition of the labelled 2-deoxyglucose solution to the cells. The net uptake of 2-deoxyglucose was then calculated.
Statistical analysis. All results were expressed as means ± SEM (n = 4 to 9). Statistical analysis of the data was done using ANOVA. A p value of less than 0.05 was considered significant. The experiments presented are representative of at least two separate experiments.
Results
Molecular cloning of rat PPARg1 and g2 cDNAs. . The nucleotide sequence of rat PPARg2 cDNA coding region was 90 % and 97 % identical to the human and mouse PPARg2 cDNAs, respectively [13, 20] .
Regulation of PPARg mRNA expression by inflammatory cytokines in rat mature adipocytes. Treatment with 10 nmol/l of TNF-a, IL-1a, IL-1b and LIF caused a 60±70 % reduction of PPARg mRNA expression 24 h after the incubation. Further IL-6 at a concentration of 1 nmol/l also caused a 58 % reduction and at 10 nmol/l a maximum reduction of 84 %. In contrast, 1 to 10 nmol/l TGF-b had no effect on PPARg mRNA regulation ( Fig. 2A) . To examine which isoforms of PPARg were regulated by inflammatory cytokines, we developed a RT-PCR assay that allows specific evaluation for the expressions of mRNAs encoding the rat PPARg 1 and PPARg 2 iso- forms. Our results showed that both PPARg 1 and PPARg 2 mRNAs were similarly reduced by TNF-a, IL-1a, IL-1b, IL-6 and LIF (Fig. 2B) .
Treatment with 100 mmol/l of H 2 O 2 tended to decrease PPARg mRNA expression and 500 mmol/l H 2 O 2 caused a 68 % reduction. Treatment with 100 mmol/l Lyso-PC and 1 mmol/l PMA also caused a 56 % and 74 % reduction, respectively, 24 h after the stimulation. No effect was exerted on PPARg mRNA expression by 1 mmol/l 8-Br-cAMP or 1 mmol/l 8-Br-cGMP (Fig. 2C) .
Treatment with 10 nmol/l TNF-a resulted in a time-dependent reduction in the expression of PPARg mRNA. This inhibitory action was first observed at 6 h of incubation and persisted to at least 36 h after exposure. The expression of PPARg mRNA did not statistically significantly alter in the control group during the 36-h-incubation period. The GLUT4 mRNA in the control group gradually decreased in a time-dependent manner, and TNF-a also greatly suppressed GLUT4 mRNA expression, compared with the controls (Fig. 3A) . Treatment with TNF-a (0.1±100 nmol/l) suppressed PPARg mRNA expression in a dose-dependent fashion. The maximum (83 %) decrease of PPARg gene transcript compared with the control occurred with 100 nmol/l TNF-a. The expression of LPL mRNA remained unchanged after 24 h of incubation with TNF-a (0.1±100 nmol/l) (Fig. 3B) . Similarily mRNA expression of the ob gene did not change (data not shown).
Effects of thiazolidinediones on PPARg and GLUT4 mRNA expressions in rat mature adipocytes. Troglitazone and pioglitazone caused augmentation of GLUT4 mRNA expression dose-dependently after 24 h of incubation. The maximum augmentation of GLUT4 mRNA expression compared with the vehicle that was given was 52 % and 38 % by 10 ±4 mol/l of troglitazone and pioglitazone, respectively. In contrast, 10 ±6 to 10 ±4 mol/l of troglitazone or pioglitazone exerted no effect on PPARg mRNA expression 24 h after treatment (Fig. 4) . Interaction of thiazolidinediones and TNF-a on PPARg and GLUT4 mRNA expressions in rat mature adipocytes. To explore the possible interaction of thiazolidinediones and TNF-a on PPARg expression, we examined the effect of the simultaneous treatment with thiazolidinediones and TNF-a on PPARg mRNA expression. Troglitazone (10 ±6 to 10 ±4 mol/l) or pioglitazone (10 ±5 to 10 ±4 mol/l) attenuated the inhibitory action of 10 nmol/l of TNF-a on PPARg mRNA expression 24 h after the stimulation (p < 0.05 or p < 0.01). The suppression of this expression caused by 10 nmol/l TNF-a was reversed approximately 60 % and 55 % by treatment with 10 ±4 mol/l troglitazone and 10 ±4 mol/l pioglitazone, respectively. Similar to the PPARg mRNA expression, thiazolidinediones (troglitazone or pioglitazone) also attenuated the inhibitory action of 10 nmol/l TNF-a on GLUT4 mRNA expression 24 h after the incubation. The suppression of GLUT4 mRNA expression caused by 10 nmol/l TNF-a was reversed approximately 70 % and 60 % by treatment with 10 ±4 mol/l troglitazone and 10 ±4 mol/l pioglitazone, respectively (Fig. 5A,B) . The expression of rat TNF-a receptor did not apparently alter with the treatment of TZD and TNF-a (Fig. 6) .
Effect of thiazolidinediones and TNF-a on insulinstimulated 2-deoxyglucose uptake in rat mature adipocytes. To investigate the relevance of the regulation of PPARg mRNA expression by TNF-a and thiazolidinediones, we examined the effects of both on insulin-stimulated glucose uptake under the same experimental conditions as described above. Rat mature adipocytes were incubated in insulin-free media for 24 h with 10 nmol/l TNF-a alone or in the presence of 10 ±4 mol/l troglitazone. Insulin-stimulated 2-deoxyglucose uptake was then measured. Insulin caused a 4.2 ± 0.5-fold increase of 2-deoxyglucose uptake. Incubation of cells with troglitazone alone had no effect on insulin stimulation for 2-deoxyglucose uptake compared with the control (4.1 ± 0.6-fold increase to the basal condition). When the cells were incubated with TNF-a alone, insulin-stimulated 2-deoxyglucose uptake was attenuated compared with the control (1.5 ± 0.3-fold increase) (p < 0.01). In contrast, when the cells were coincubated with TNF-a and troglitazone, insulin stimulated glucose uptake by 3. PIO 10 ±6 to 10 ±4 mol/l) and either vehicle or 10 nmol/l TNF-a. Bars represent the means ± SEM (n = 5). *p < 0.05 and **p < 0.01 compared with corresponding control values fect of TNF-a on insulin-stimulated glucose uptake (p < 0.01) (Fig. 7) .
Discussion
Peroxisome proliferator-activated receptors are a family of nuclear receptors comprising three subtypes of designated isoforms, PPARa, PPARg and PPARd (also termed PPARb, FAAR, or NUC-1) with different and specific tissue distributions [21] . The isoform PPARg is a relatively newly discovered member of the PPAR family that has been suggested to be involved in the regulation of not only adipocyte differentiation but also lipid metabolism and insulin action. Recent studies showed that the insulin-sensitizing thiazolidinedione class of compounds are synthetic ligands for PPARg and there seems to be a close relation between the potency of various thiazolidinediones to stimulate PPARg and their anti-diabetic action [22] . Although a large number of experimental rat models of obesity and insulin resistance have been used to study the pathogenesis, therapy and prevention of diabetes [23] , molecular cloning of PPARg1 and g2 cDNAs have been reported only in mice and humans [13, 20] . In our study, we succeeded in isolating and determining the sequence of rat PPARg1 and g2 cDNAs. Nucleotide and deduced amino acid sequences analysis showed that the rat PPARg1 and g2 proteins are 475 and 505 amino acid polypeptides, respectively, with putative signal sequences. The structure of the rat PPARg1 and g2 proteins explained in this study are highly homologous to those of the mouse and human PPARg1 and g2 proteins. These observations indicate that the structure of rat PPARg1 and g2 proteins are evolutionarily conserved among species.
In our study, using rat mature adipocytes, we examined the effect of inflammatory cytokines on the regulation of rat PPARg mRNA expression, and moreover investigated the interaction of thiazolidinediones and TNF-a, which is one of the best characterized inflammatory cytokines produced in adipocytes and has been suggested as having a role in insulin resistance [3] .
In this study, inflammatory cytokines such as TNF-a, IL-1a, IL-1b, IL-6 and LIF potently induced down regulation of PPARg mRNA expression in rat mature adipocytes. The isoforms PPARg1 and PPARg2 were shown to be similarly reduced by inflammatory cytokines. Time-dependent and concentration-dependent reduction in PPARg expression by TNF-a in mature adipocytes is consistent with a recent report on 3T3L1 adipocytes [24] , which are a heteroploid cell line derived originally from mouse embryonic fibroblasts. It has also been reported that infusion of TNF-a into mice in vivo resulted in decreased PPARg mRNA expression [25] . A recent study showed that infusion of rats with TNF-a resulted in a pronounced insulin resistance as measured by peripheral glucose disposal and hepatic glucose uptake [26] . Moreover, neutralization of endogenous TNF-a by TNF-a receptor-IgG fusion protein improves peripheral insulin sensitivity in obese rats [27] . Thus, TNF-a is considered to be the most probable candidate cytokine related to insulin resistance. In addition, previous studies have also shown that IL-1, IL-6, and LIF concentrations are increased in the sera of patients with infectious diseases, cancer and acquired immuno deficiency syndromes, in which insulin action is impaired [2, 6] . Infusions of IL-1, IL-6 into rats have been shown to cause suppression of peripheral glucose uptake [4, 8] . Thus, IL-1, IL-6 and LIF could be other candidates for causing the development of insulin resistance in these diseases. In this study, we showed that some of the inflammatory cytokines, including TNF-a, could reduce PPARg mRNA expression in the adipocytes. We, therefore, suggest that the decrease in both PPARg1 and PPARg2 expressions might be the cause of insulin resistance in wasting syndromes in which inflammatory cytokines have a central role. It has been, however, recently shown that the adipose expression of PPARg mRNA is increased in human obesity [28] . Thus, insulin resistance in inflammation may not be regulated similarly to insulin resistance in obesity and Type II diabetes.
We also examined the effects of intracellular signalling molecules, such as H 2 O 2 , Lyso-PC or PMA on PPARg expression, and we showed that PPARg mRNA expression was suppressed considerably by H 2 O 2 , Lyso-PC or PMA. Recent epidemiological and clinical evidence that hyperglycaemia has a role in the development of insulin resistance (glucose toxicity) has been reported [29] . Several laboratories have shown that increased plasma and tissue glucose concentrations could be one of the important sources of the increased oxygen-derived free radicals seen in diabetic patients [30, 31] . Glucose can be oxidized to generate free radicals and H 2 O 2 . Lyso-PC is also generated during the process of oxidative modification. Furthermore, it was reported that pharmacologic vitamin E (antioxidant) supplementation in patients with Type II diabetes improves insulin resistance [32] . Although in another series of our experiments, exposure to high glucose (20 mmol/l) for 24 h showed only a tendency to decrease PPARg mRNA expression (Tanaka et al. unpublished data), suppression of PPARg mRNA expression by H 2 O 2 or Lyso-PC observed in the present study can be related to insulin resistance in hyperglycaemia.
It has been recently reported that insulin increases production of H 2 O 2 in adipocytes. Exposure of human adipocytes to increasing concentrations of insulin (10 ±11 to 10 ±7 mol/l) led to a dose-dependent increase in H 2 O 2 generation [33, 34] . There are also several reports that show that H 2 O 2 is a potent insulin mimicker. Exogenously supplied H 2 O 2 has been shown to bring about a range of metabolic effects that are similar to those seen with insulin. In rat primary adipocytes, H 2 O 2 (0.3±4 mmol/l) stimulated glucose uptake [35, 36] . It has been therefore proposed that H 2 O 2 can act as a second messenger for insulin. In our preliminary experiments, treatment with insulin also suppressed PPARg mRNA expression. Therefore suppression of PPARg mRNA expression by H 2 O 2 can be relevant to hyperinsulinaemia associated with insulin resistance.
In this study, we show that thiazolidinediones strongly restored PPARg mRNA expression that had been suppressed by TNF-a. Previous studies showed several antagonizing actions of thiazolidinediones and TNF-a, including the adipocyte differentiation in vitro [37, 38] . Moreover, insulin resistance caused by infusion of TNF-a in vivo has been shown to be prevented by treatment with troglitazone [9] . Our results indicate that PPARg expression itself is another site of interaction of thiazolidinediones and TNF-a. We also show that thiazolidinediones augmented the expression of GLUT4 in the presence and absence of TNF-a in our primary culture adipocytes. This finding is compatible with previous reports using 3T3L1 adipocytes [37, 38] . It has also been reported that thiazolidinediones restore the decreased GLUT4 expression in obese Zucker rat in vivo [39] . We speculate that the effect of thiazolidinediones in returning PPARg expression to normal observed in our study is related to one of the mechanisms for the restoration of the suppression of GLUT4 expression by thiazolidinediones induced by TNF-a. In our study, we showed that the expression of the TNF-a receptor did not appear to change after treatment with thiazolidinediones and TNF-a. Thiazolidinediones are not, therefore, considered to influence the action of TNF-a by changing TNF-a receptor expression. In our culture system without TNF-a treatment, an increase of GLUT4 mRNA expression by thiazolidinediones was accompanied by no change of PPARg mRNA expression. We speculate that PPARg mRNA expression is up regulated in the basal condition and we could not detect the augmentation of PPARg mRNA expression.
The question addressed by our study was whether the amount of PPARg mRNA affects the amelioration of insulin resistance. We, therefore, examined insulin-stimulated 2-deoxyglucose uptake in adipocytes treated with TNF-a and thiazolidinediones in our experimental conditions. Our results indicate that thiazolidinediones improve the suppression of insulinstimulated glucose uptake by TNF-a in adipocytes where they, in parallel, restore the decreased PPARg and GLUT4 expressions by TNF-a. We suggest that thiazolidinediones may ameliorate insulin resistance in part by restoring the decreased PPARg and GLUT4 expressions in adipocytes to normal in the situation of TNF-a or other cytokines-related insulin resistance such as cachexia in chronic infection, chronic inflammatory diseases and neoplastic diseases.
In conclusion, we carried out the isolation and sequence determination of rat PPARg1 and g2 cDNAs. Inflammatory cytokines such as TNF-a, IL1a, IL-1b, IL-6 and LIF reduced the expression of rat PPARg mRNA. Thiazolidinediones protected the expression of PPARg and GLUT4 mRNA from decreasing in the presence of TNF-a. These findings suggest that the regulation of PPARg mRNA expression by thiazolidinediones contributes to their antidiabetic mechanism.
